We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+25.21%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$13.9M
AUM Growth
-$44.5M
Cap. Flow
-$44.7M
Cap. Flow %
-320.95%
Top 10 Hldgs %
48.07%
Holding
80
New
14
Increased
3
Reduced
23
Closed
39
Avg Time Held Equity + Options
3.3 quarters
Top 10 Avg Time Held Equity + Options
0.6 quarters
Top 20 Avg Time Held Equity + Options
0.9 quarters
Avg Time Held Equity only
3.3 quarters
Top 10 Avg Time Held Equity only
0.6 quarters
Top 20 Avg Time Held Equity only
1.2 quarters

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$510K
2
ELV icon
Elevance Health
ELV
+$459K
3
HUM icon
Humana
HUM
+$427K
4
CNC icon
Centene
CNC
+$371K
5
PFE icon
Pfizer
PFE
+$281K

Top Sells

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$2.23M
2
MCHP icon
Microchip Technology
MCHP
+$2.23M
3
ZBH icon
Zimmer Biomet
ZBH
+$1.99M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.81M
5
TWLO icon
Twilio
TWLO
+$1.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Miscellaneous 0.9%
3 Communication Services 0%
4 Consumer Discretionary 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BOLD icon
1
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.06M 7.65%
17,795
-7,575
-30% -$284K
2018 Q2
6 quarters
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$911K 6.54%
8,421
-13,715
-62% -$1.47M
2019 Q3
1 quarter
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$776K 5.57%
284,285
– –
2017 Q4
8 quarters
GILD icon
4
Gilead Sciences
GILD
$187B
$708K 5.08%
10,898
-17,604
-62% -$1.15M
2019 Q2
2 quarters
PEN icon
5
Penumbra
PEN
$12.6B
$608K 4.37%
3,699
-8,859
-71% -$1.41M
2016 Q3
13 quarters
ZBH icon
6
Zimmer Biomet
ZBH
$17.6B
$552K 3.96%
3,800
-14,419
-79% -$1.99M
2017 Q4
8 quarters
BIIB icon
7
Biogen
BIIB
$33.9B
$546K 3.92%
+1,839
New +$510K
2019 Q4
0 quarters
NVRO icon
8
DELISTED
NEVRO CORP.
NVRO
$531K 3.81%
4,515
-1,252
-22% -$124K
2018 Q4
4 quarters
ELV icon
9
Elevance Health
ELV
$91.5B
$504K 3.62%
+1,669
New +$459K
2019 Q4
0 quarters
HUM icon
10
Humana
HUM
$52.1B
$494K 3.55%
+1,347
New +$427K
2019 Q4
0 quarters
CI icon
11
Cigna
CI
$74.9B
$453K 3.25%
2,216
-4,916
-69% -$901K
2019 Q3
1 quarter
IQV icon
12
IQVIA
IQV
$43.2B
$452K 3.25%
2,926
-5,641
-66% -$824K
2019 Q1
3 quarters
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$10.7B
$451K 3.24%
5,329
-24,012
-82% -$1.81M
2019 Q2
2 quarters
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
$436K 3.13%
18,035
+1,304
+8% +$27K
2019 Q3
1 quarter
AGN
15
DELISTED
Allergan plc
AGN
$436K 3.13%
2,282
-5,092
-69% -$919K
2019 Q1
3 quarters
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$431K 3.09%
9,484
-19,393
-67% -$917K
2018 Q2
6 quarters
CNC icon
17
Centene
CNC
$33.1B
$430K 3.09%
+6,838
New +$371K
2019 Q4
0 quarters
NVS icon
18
Novartis
NVS
$273B
$392K 2.81%
4,270
-6,441
-60% -$578K
2019 Q3
1 quarter
HCA icon
19
HCA Healthcare
HCA
$99.3B
$345K 2.48%
2,335
-5,165
-69% -$694K
2017 Q4
8 quarters
PFE icon
20
Pfizer
PFE
$162B
$294K 2.11%
+7,897
New +$281K
2019 Q4
0 quarters
ICUI icon
21
ICU Medical
ICUI
$4.1B
$258K 1.85%
+1,381
New +$238K
2019 Q4
0 quarters
DERM icon
22
DELISTED
Dermira, Inc.
DERM
$256K 1.84%
16,892
-13,106
-44% -$113K
2019 Q1
3 quarters
ICLR icon
23
Icon
ICLR
$12.7B
$241K 1.73%
1,402
-1,810
-56% -$279K
2019 Q2
2 quarters
UNH icon
24
UnitedHealth
UNH
$340B
$233K 1.67%
+791
New +$207K
2019 Q4
0 quarters
IRTC icon
25
iRhythm Holdings
IRTC
$3.52B
$231K 1.66%
3,389
-9,372
-73% -$636K
2018 Q2
6 quarters
1
2 3 4

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q4 2019 Portfolio in Review

As of Q4 2019, Partner Investment Management held 80 positions worth $13.9M, down 76% from $58.4M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Partner Investment Management withdrew a net $44.7M in Q4 2019, closing 39 positions and reducing 23 holdings. Its most notable exit was NXP Semiconductors, an estimated $2.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 53% a quarter earlier, followed by Miscellaneous and Communication Services.

Against the trend, Partner Investment Management opened a new position in Biogen worth $546K.

  • Partner Investment Management's largest Q4 2019 buy was Biogen: 1,839 shares worth $546K.
  • Partner Investment Management added most to Axonics, Inc. Common Stock in Q4 2019, an estimated $48.7K increase.
  • Partner Investment Management's biggest Q4 2019 reduction was Zimmer Biomet, cutting an estimated $1.99M.
  • Partner Investment Management fully exited NXP Semiconductors in Q4 2019, selling an estimated $2.23M.
  • Partner Investment Management's ten largest holdings make up 48% of its $13.9M portfolio in Q4 2019.
  • Partner Investment Management opened 14 new positions and closed 39 in Q4 2019.
  • Partner Investment Management's portfolio value fell 76% quarter-over-quarter to $13.9M.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.